Interested in ConvaTec Group PLC? Here are five stocks we like better.
ConvaTec maintained its 2026 targets after delivering 5% first-half organic revenue growth excluding InnovaMatrix, 6% adjusted EPS growth and a 21.2% operating margin. Management expects stronger second-half growth, particularly in Infusion Care, and reaffirmed double-digit full-year EPS growth.
InnovaMatrix remains a significant headwind: first-half sales dropped to £2.5 million, prompting a £69 million non-cash impairment charge and reducing full-year revenue expectations to £5 million–£10 million. The company expects the product to approach breakeven in the second half as U.S. market conditions stabilize.
Shareholder returns and future investment increased: ConvaTec raised its interim dividend by 15% and launched a £200 million share buyback, while investing about $90 million in 2026 growth capital—primarily to expand Infusion Care capacity and support its product pipeline.
ConvaTec Group (LON:CTEC) said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product.
#Growth #group
ConvaTec maintained its 2026 targets after delivering 5% first-half organic revenue growth excluding InnovaMatrix, 6% adjusted EPS growth and a 21.2% operating margin. Management expects stronger second-half growth, particularly in Infusion Care, and reaffirmed double-digit full-year EPS growth.
InnovaMatrix remains a significant headwind: first-half sales dropped to £2.5 million, prompting a £69 million non-cash impairment charge and reducing full-year revenue expectations to £5 million–£10 million. The company expects the product to approach breakeven in the second half as U.S. market conditions stabilize.
Shareholder returns and future investment increased: ConvaTec raised its interim dividend by 15% and launched a £200 million share buyback, while investing about $90 million in 2026 growth capital—primarily to expand Infusion Care capacity and support its product pipeline.
ConvaTec Group (LON:CTEC) said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product.
#Growth #group
1 month ago
